Product Center
Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-12-30
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) have been recognized as a Jiangsu Province Specialized and Innovative Small and Medium-Sized Enterprise and a National High-Tech Enterprise, respectively.
Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification!
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) have been recognized as a Jiangsu Province Specialized and Innovative Small and Medium-Sized Enterprise and a National High-Tech Enterprise, respectively.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-12-30 11:32
- Views:
Recently, Ab&B Bio-Tech Co., Ltd. (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) have been recognized as a Jiangsu Province Specialized and Innovative Small and Medium-Sized Enterprise and a National High-Tech Enterprise, respectively.
Specialized, Refined, Unique, and Innovative Small and Medium-Sized Enterprises refer to those that focus on segmented markets, have outstanding innovation capabilities, a high market share, and strong development potential. The acquisition of this title represents authoritative recognition of the enterprise's specialization, refinement, uniqueness, and innovation. Ab&B Bio will also adhere to an innovation-driven approach, making products more specialized, quality more refined, and its brand stronger, so that China can use global innovative vaccines and the world can use high-quality Chinese vaccines.
The recognition of a National High-Tech Enterprise is one of the most authoritative evaluations of a company's comprehensive strength in the field of scientific and technological innovation. This recognition is a comprehensive assessment by authoritative national departments of the research and development management level, the quantity and quality of independent intellectual property rights, the ability to transform scientific and technological achievements, growth potential, and talent structure of the enterprise, reflecting high recognition of its innovation capability and development potential. Yither Bio will continue to enhance its research and development capabilities, accelerate the transformation of scientific and technological achievements, and provide a source of vitality for the company's innovative vaccine development.
Relevant information
-
Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going globalOn March 13, 2026, Ab&B Bio-Tech Co., Ltd. (hereinafter referred to as "Ab&B Bio") and Walvax Biotechnology Co., Ltd. (hereinafter referred to as "Walvax") officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines in Taizhou. Both parties announced that they will jointly promote the development of the influenza virus subunit vaccine independently developed by Ab&B Bio and set sail to the sea. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field. - Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi 03-04
- Announcement of Pre increase in Performance for 2025 Released 02-26
- Ab&B Bio-Tech Co., Ltd. has been included in the Hang Seng Composite Index, and its recognition in the capital market continues to increase 02-16
- The study on pregnant women receiving quadrivalent influenza virus subunit vaccine has successfully completed key enrollment 02-10
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
